Advanced search
Publication Cover
Journal of Market Access & Health Policy Volume 5, 2017 - Issue 1
Journal homepage
802
Views
2
CrossRef citations to date
0
Altmetric
Article

A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting

Clément FrançoisHealth Economics Outcome Research, Lundbeck, Deerfield, IL, USACorrespondence[email protected]
View further author information
,
Alice Guiraud-DiawaraHealth Economics Outcome Research, Lundbeck SAS, Issy-les-Moulineaux, FranceView further author information
,
Christophe LançonLaboratoire de Santé Publique Évaluation des Systèmes de Soins et Santé Perçue, Université de la Méditerranée – EA 3279 – Faculté de Médecine, Marseille 5, FranceView further author information
,
Pierre Michel LlorcaCentre Hospitalier Universitaire Clermont-Ferrand, EA 7280 Université Clermont-Auvergne, Clermont Ferrand, FranceORCID Iconhttp://orcid.org/0000-0001-7438-8990View further author information
ORCID Icon,
Ann HartryHealth Economics Outcome Research, Lundbeck, Deerfield, IL, USAView further author information
,
Lene Hammer-HelmichHealth Economics Outcome Research, Lundbeck A/S, Valby, DenmarkView further author information
,
Djamel A. ZighedERIC Lab, Université de Lyon, Bron, FranceView further author information
,
Adrian TanasescuRithme Consulting, Villeurbanne, FranceView further author information
&
Mondher ToumiDepartment of Public Health, Aix Marseille University, Marseille 5, FranceView further author information
 show all
Article: 1372026 | Received 27 Mar 2017, Accepted 21 Aug 2017, Published online: 13 Sep 2017

References

  • Voruganti L, Cortese L, Oyewumi L, et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res. 2000;43:1–10.
  • Ashoorian D, Davidson R, Rock D, et al. A review of self-report medication side effect questionnaires for mental health patients. Psychiatry Res. 2014;219:664–673.
  • Hamer S, Haddad PM. Adverse effects of antipsychotics as outcome measures. Br J Psychiatry Suppl. 2007;50:s64–s70.
  • Weiden PJ. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J Clin Psychiatry. 2007;68(Suppl 1):12–19.
  • Pritchett YL, Tamura R. Global benefit-risk assessment in designing clinical trials and some statistical considerations of the method. Pharm Stat. 2008;7:170–178.
  • Cha DS, McIntyre RS. Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opin Pharmacother. 2012;13:1587–1598.
  • Rapaport M, Barbato LM, Heisterberg J, et al. Efficacy and safety of bifeprunox versus placebo in the treatment of patients with acute exacerbations of schizophrenia. Presented at: American College of Neuropsychopharmacology, 2006 Dec 3–7; Hollywood, FL, USA.
  • Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–962.
  • Young SL, Taylor M, Lawrie SM. “First do no harm.” A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol. 2015;29:353–362.
  • Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31–41.
  • Dunayevich E, Ascher-Svanum H, Zhao F, et al. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. J Clin Psychiatry. 2007;68:1163–1171.
  • Thomas P. The stable patient with schizophrenia – from antipsychotic effectiveness to adherence. Eur Neuropsychopharmacol. 2007;17(Suppl 2):S115–22.
  • Bech P. Quality of life measurements in chronic disorders. Psychother Psychosom. 1993;59:1–10.
  • Bech P. Quality of life measurement in the medical setting. Eur Psychiatry. 1995;10(Suppl 3):83s–5s.
  • Gerlach J, Korsgaard S, Clemmesen P, et al. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr Scand. 1993;87:244–252.
  • Wolters HA, Knegtering H, Van Den Bosch RJ, et al. Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales. Schizophr Res. 2009;112:114–118.
  • Waddell L, Taylor M. A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. J Psychopharmacol. 2008;22:238–243.
  • Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1–100.
  • Day JC, Wood G, Dewey M, et al. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry. 1995;166:650–653.
  • Weiden PJ, Miller AL. Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications. J Psychiatr Pract. 2001;7:41–47.
  • Bebbington PE, Angermeyer M, Azorin JM, et al. Side-effects of antipsychotic medication and health-related quality of life in schizophrenia. Acta Psychiatr Scand Suppl. 2009;22–28.
  • McTaggart-Cowan HM, Shi P, Fitzgerald JM, et al. An evaluation of patients’ willingness to trade symptom-free days for asthma-related treatment risks: a discrete choice experiment. J Asthma. 2008;45:630–638.
  • Seston EM, Ashcroft DM, Griffiths CE. Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis. Arch Dermatol. 2007;143:1175–1179.
  • Harris G. Wife’s cancer prods F.D.A. on new drugs. New York Times. January 3, 2016;A: 1.
  • Xiao C, Polomano R, Bruner DW. Comparison between patient-reported and clinician-observed symptoms in oncology. Cancer Nurs. 2013;36:E1–E16.
  • Laugsand EA, Sprangers MA, Bjordal K, et al. Health care providers underestimate symptom intensities of cancer patients: a multicenter European study. Health Qual Life Outcomes. 2010;8:104.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.